Clinical trials: Behaviour
Bipolar Depression, Suicidal Ideas
Sequential Therapy for the Treatment of Severe Bipolar Depression.
NeuroRx is developing NRX-101, a fixed-dose combination oral capsule composed of d-cycloserine (DCS) and lurasidone for the maintenance of remission from Severe Bipolar Depression with Acute Suicidal Ideation (C-SSRS level 4 or…
- Conditions
- Bipolar Depression, Suicidal Ideas, Suicidal Ideation, Suicide, Attempted
- Trial name
- STABIL-B (NCT02974010)
- Testing
- NRX-101 Oral Capsule, Lurasidone Oral Capsule, Ketamine Intravenous Infusion
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- NeuroRx, Inc.
Pulmonary Disease, Chronic Obstructive
TARA Working Prototype [Version 2]: Feasibility Study
TARA is a Digital Behaviour Change Intervention (DBCI) for Individuals with COPD (IwCOPD), which has been designed using a Human-Centred Design (HCD) methodology.
- Trial name
- NCT04320524
- Testing
- Technology-Assisted Respimat Adherence Digital Behaviour Change Intervention
- Sponsor
- Boehringer Ingelheim
Depressive Disorder
Study to Evaluate the Safety and Efficacy of PEER Interactive Versus Treatment as Usual in Subjects With a Primary Diagnosis of Depression
This is a prospective, multicenter, randomized, double-blind, controlled study to evaluate the effectiveness of PEER Interactive to inform treatment in subjects with a primary diagnosis of depression with comorbidity of…
- Trial name
- NCT01794559
- Testing
- PEER Interactive Report
- Where
- 2 sites in United States
- Volunteers
- 1,922 people
- Sponsor
- MYnd Analytics
Fasting
Bioequivalence Study of Metformin Hydrochloride Extended-Release Tablets USP 750 mg Under Fed Condition
The study was a randomized, open label, two-treatment, two-period, two-sequence, single dose, crossover, oral bioequivalence study in normal, healthy adult human subjects under fed condition.
- Trial name
- NCT01831674
- Testing
- Metformin Hydrochloride Extended-Release Tablets USP 750, GLUCOPHAGE®XR tablet 750 mg
- Where
- India
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- IPCA Laboratories Ltd.
Chronic Kidney Disease Stage 3B, Chronic Kidney Disease stage4
Low-Protein Diet With Low-Protein Foods Versus a LPD Without LP Foods in Patients With Chronic Kidney Disease (CKD)
The KDOQI 2020 - Clinical practice guideline for nutrition in chronic kidney disease (CKD) -recommends protein restriction to reduce the risk of end-stage renal disease/death and improve quality of life, a low protein diet…
- Conditions
- Chronic Kidney Disease Stage 3B, Chronic Kidney Disease stage4, Chronic Kidney Disease Stage 5, Chronic Kidney Disease Stage 3A
- Trial name
- NCT05489120
- Testing
- Consumption of FLAVIS
- Where
- 18 sites in France
- Volunteers
- 210 people
- Sponsor
- Dr. Schär AG / SPA
Self-care, Compassion Satisfaction
Effect of Self-care Skill Education on the Compassionate Satisfaction and Compassionate Fatigue Among Clinical Nurses Clinical Nurses at HMC
The health of our nurses is perhaps the most important consideration for delivering excellent patient care. The passionate approach of nurses can lead to a lot of fatigue and stress among nurses.
- Conditions
- Self-care, Compassion Satisfaction, Compassion Fatigue, Educational Intervention
- Trial name
- NCT05983497
- Testing
- Self-Care Skill Educational Intervention
- Where
- Qatar
- Volunteers
- 248 people, healthy volunteers welcome
- Sponsor
- Hamad Medical Corporation
Major Depressive Disorder
Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo and Active Control in Major Depressive Disorder
This study is to evaluate that (SEROQUEL®) quetiapine sustained-release is efficacious and safe in the treatment of patients with MDD.
- Trial name
- DIAMOND (NCT00321490)
- Testing
- Quetiapine fumarate, Duloxetine
- Where
- 34 sites in United States
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Addictive Behavior, Alcohol Use Disorder
90-Day Online Substance Use Program
Individuals indicating risky substance use are randomly assigned either to a three-month online intervention on the Workit Health platform or a waitlist/treatment as usual.
- Conditions
- Addictive Behavior, Alcohol Use Disorder, Alcohol Abuse, Drug Abuse
- Trial name
- NCT03069118
- Testing
- Treatment - Workit Health Online Program, Control - Resource List
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Workit Health
Healthy Volunteers
Performance of the ID-Cap System, an Ingestion Event Marker, in the Clinical Setting as an Aid to Measure Medication Adherence
The ID-Cap System is classified as an ingestion event marker (IEM), a Class II medical device. The system is intended to record time-stamped ingestions with the ingestible sensor, ID-Tag which transmits a signal to a wearable…
- Trial name
- NCT03653897
- Testing
- ID-Capsule- Active, Wearable Sensor
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- EtectRX, Inc.
Dementia
A Study on Behavioral and Psychological Symptoms of Dementia
The purpose of this observational study is to obtain the current status of patients with Behavioral and Psychological Symptoms of Dementia.
- Trial name
- NCT00641459
- Testing
- Observational BPSD treatment study
- Volunteers
- 359 people
- Sponsor
- Johnson & Johnson Taiwan Ltd
Attention Deficit Disorder With Hyperactivity
Classroom Study to Assess Efficacy and Safety of MTS in Pediatric Patients Aged 6-12 With ADHD
Evaluate the behavioral effects of MTS in children aged 6-12 with ADHD
- Trial name
- NCT00466791
- Testing
- Methylphenidate Transdermal System
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- Noven Therapeutics
Depression, Anxiety
Aiberry AI Mental Health Screening Platform
Aiberry is creating a multi-modal artificial intelligence (AI) platform that analyzes facial, audio and text features to screen for mental illness.
- Conditions
- Depression, Anxiety, Healthy
- Trial name
- NCT04994899
- Where
- 3 sites in United States
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Aiberry, Inc
Smoking Cigarette
A Consumer Use Behavior Study to Evaluate Puffing Topography and Average Daily Consumption of Heated Tobacco Products
This is a parallel design cohort consumer use study to measure the puffing topography of two HTP devices, with three variants of HTP consumables ("sticks,"), collectively referred to as the study investigational products (Study…
- Trial name
- NCT07175987
- Testing
- RDTH002581, RDTH002580, RDTH002582
- Where
- United Kingdom
- Volunteers
- 212 people, healthy volunteers welcome
- Sponsor
- RAI Services Company
Renal Insufficiency
Assessing the Behavior of Met DR in Subjects With Kidney Dysfunction
This study evaluated how a single dose of delayed-release metformin (Met DR) behaves in subjects with normal kidney function, mild kidney dysfunction, moderate kidney dysfunction, or severe kidney dysfunction.
- Trial name
- NCT01658514
- Testing
- Met DR, Met XR
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Elcelyx Therapeutics, Inc.
Depression
Positron Emission Tomography (PET) Study With [11C]Raclopride to Determine Central D2 Dopamine Occupancy of SEROQUEL
The aim of this study is to relate pharmacokinetics of two different formulations of quetiapine to PET measured receptor occupancy in the brains of healthy subjects.
- Trial name
- PET (NCT00832221)
- Testing
- SEROQUEL XR (quetiapine), SEROQUEL IR (quetiapine), radioligand [11C]raclopride
- Where
- Sweden
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Major Depressive Disorder
Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder
This is a phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-arm trial to assess the efficacy, safety, and tolerability of centanafadine once-daily (QD) extended-release (XR) capsules for the treatment…
- Trial name
- JUNIPER (NCT05536414)
- Testing
- Centanafadine, Escitalopram
- Where
- 62 sites in United States
- Volunteers
- 337 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
ADHD
An Adjunct Study to Assess Guided ADHD Therapy for Managing the Extent and Severity of Symptoms
The objective of this study is to assess the safety and effectiveness of an at-home, game-based digital therapy for treating adult patients with Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- A-GAMES (NCT05805176)
- Testing
- ADHD Therapy
- Where
- 5 sites in United States
- Volunteers
- 194 people
- Sponsor
- Lumos Labs, Inc.
Smoking Cessation
Personalized Smoking Cessation Tool Based on Patient Lung CT Image
Imbio is developing a Smoking Cessation Report (Report) that includes data analysis from a CT lung cancer screening exam. This randomized controlled (RCT) trial will clinically validate the Report's effectiveness at motivating…
- Trial name
- NCT03087617
- Testing
- Imbio Smoking Cessation Report, Smoking Cessation Counseling, Usual Care
- Where
- United States
- Volunteers
- 321 people
- Sponsor
- Imbio
Attention Deficit Hyperactivity Disorder
Software Treatment for Actively Reducing Severity of ADHD in Adolescents (STARS-ADHD-Adolescents)
The purpose of this study is to evaluate the effects of videogame-like digital therapy on attentional functioning and symptoms in adolescents ages 13-17 diagnosed with ADHD
- Trial name
- NCT04897074
- Testing
- AKL-T01
- Where
- 14 sites in United States
- Volunteers
- 165 people
- Sponsor
- Akili Interactive Labs, Inc.
Major Depressive Disorder
Open-label Long Term (52 Weeks) Safety and Tolerability of Agomelatine Sublingual Tablets in Major Depressive Disorder (MDD)
The study will assess safety and tolerability of 0.5 mg/day and 1 mg/day of sublingual (under the tongue) formulation of agomelatine (AGO178) in patients with Major Depressive Disorder over a 52-week open-label phase.
- Trial name
- NCT01156415
- Testing
- AGO178
- Where
- 98 sites in United States, Puerto Rico
- Volunteers
- 837 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.